GLV-1h68 vaccinia virus therapy of neuroendocrine tumors

Background: Oncolytic virotherapy is an upcoming treatment option for many tumor entities. But so far, a first oncolytic virus only was approved for advanced stages of malignant melanomas. Neuroendocrine tumors (NETs) constitute a heterogenous group of tumors arising from the neuroendocrine system at diverse anatomic sites. Due to often slow growth rates and (in most cases) endocrine non-functionality, NETs are often detected only in a progressed metastatic situation, where therapy options are still severely limited. So far, immunotherapies and especially immunovirotherapies are not established as novel treatment modalities for NETs. Methods: In this immunovirotherapy study, pancreatic NET (BON-1, QGP-1), lung NET (H727, UMC-11), as well as neuroendocrine carcinoma (NEC) cell lines (HROC-57, NEC-DUE1) were employed. The well characterized genetically engineered vaccinia virus GLV-1h68, which has already been investigated in various clinical trials, was chosen as virotherapeutical treatment modality. Results: Profound oncolytic efficiencies were found for NET/NEC tumor cells. Besides, NET/NEC tumor cell bound expression of GLV-1h68-encoded marker genes was observed also. Further­more, a highly efficient production of viral progenies was detected by sequential virus quantifications. More­over, prospects of a combinatorial treatment of GLV-1h68 with the mTOR inhibitor everolimus, licensed for treatment of metastatic NETs, were assessed successfully. Conclusions: In summary, the oncolytic vaccinia virus GLV-1h68 was found to exhibit promising antitumoral activities, replication capacities and a potential for future combinatorial approaches. This has been shown in a widespread spectrum of cancers in a preclinical setting and now has to be further evaluated for treatment of metastatic neuroendocrine cancer.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  2020-01-14

• Fields of study

  Not labeled

• Identifiers
  DOI 10.21203/rs.2.20785/v1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma

  2019cited by this paper
• Neues zur Therapie von neuroendokrinen Tumoren des gastroenteropankreatischen Systems

  2019cited by this paper
• Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro

  2019cited by this paper
• First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

  2019cited by this paper
• Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms

  2019cited by this paper
• The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines

  2019cited by this paper
• Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis

  2018cited by this paper
• Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8+ T cell proliferation

  2018cited by this paper
• Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.

  2018cited by this paper
• Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

  2018cited by this paper
• Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma

  2017cited by this paper
• Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments

  2017cited by this paper
• Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets

  2017cited by this paper
• Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis

  2017cited by this paper
• Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine

  2017cited by this paper
• Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor

  2016cited by this paper
• Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma

  2016cited by this paper
• Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions

  2015cited by this paper
• Changes in the Epidemiology of Neuroendocrine Tumours

  2015cited by this paper
• Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma

  2015cited by this paper
• Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

  2015cited by this paper
• Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling

  2014cited by this paper
• Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

  2014cited by this paper
• New Model for Gastroenteropancreatic Large-Cell Neuroendocrine Carcinoma: Establishment of Two Clinically Relevant Cell Lines

  2014cited by this paper
• Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68

  2013cited by this paper
• Virotherapy of Neuroendocrine Tumors

  2012cited by this paper
• Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts

  2012cited by this paper
• Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

  2011cited by this paper
• Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

  2011cited by this paper
• Cryopreservation of human colorectal carcinomas prior to xenografting

  2010cited by this paper
• Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma

  2010cited by this paper
• Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

  2009cited by this paper
• Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy

  2009cited by this paper
• ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors

  2009influential reference
• Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

  2009cited by this paper
• Molecular mechanisms of mTOR-mediated translational control

  2009cited by this paper
• The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation

  2009cited by this paper
• Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.

  2008cited by this paper
• Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.

  2007influential reference
• Dynamic monitoring of cytotoxicity on microelectronic sensors.

  2005cited by this paper
• Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei.

  2001cited by this paper
• Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

  1999cited by this paper
• The human carcinoid cell line, BON. A model system for the study of carcinoid tumors.

  1994cited by this paper
• Neuromedin B is present in lung cancer cell lines.

  1992cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• p53: a frequent target for genetic abnormalities in lung cancer.

  1989cited by this paper
• Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma.

  1980cited by this paper

• No citing papers are available for this paper.